IL-17A Inhibition in Plaque Psoriasis

How does IL-17A inhibition affect inflammatory pathways in plaque psoriasis?

IL-17A inhibition produces rapid and comprehensive suppression of inflammatory pathways in plaque psoriasis by interrupting the IL-23/Th17 axis and neutrophil-keratinocyte crosstalk, achieving nearly complete pathway normalization within 12 weeks.

Abstract

IL-17A inhibition produces rapid, comprehensive, and sustained effects on inflammatory pathways in plaque psoriasis. Across 10 studies examining secukinumab, ixekizumab, and AIN457 in moderate-to-severe disease, pathway suppression begins within 1 week of treatment, with clearance of cutaneous neutrophils and normalization of keratinocyte abnormalities evident by 2 weeks. The magnitude of effect increases progressively, achieving 89-97% resolution of psoriasis-associated expression differences by 12 weeks and sustained suppression through 52 weeks. IL-17A functions as a critical node within the IL-23/Th17 axis, with its inhibition producing cascading effects that include reductions in upstream IL-23, downstream targets like beta-defensin2, and complete depletion of IL-17-producing T cell populations. The mechanism involves interruption of a neutrophil-keratinocyte crosstalk and normalization of inflammatory gene expression rather than mere immune suppression, with promotion of regulatory dendritic cell populations. Compared to IL-23 inhibition, IL-17A blockade produces faster normalization of cell proliferation pathways at 4 weeks and greater reductions in systemic inflammatory markers at 16 weeks, though IL-23 inhibition shows greater effects on immune processes by 24-48 weeks, reflecting their differential positions in the inflammatory cascade.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200

• Papers screened using: Population - Target Condition, Population - Condition Specificity, Intervention - IL-17A Inhibitors, Intervention - Specificity, Outcomes - Inflammatory Measures, Study Design - Quality, Treatment Duration, Confounding Factors - Patient Population, Confounding Factors - Concurrent Treatments

• n = 200 Papers screened out

• n = 190

• Papers included for extraction

• n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “How does IL-17A inhibition affect inflammatory pathways in plaque psoriasis?”

• The search returned 200 total results from Elicit.
• We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• Population - Target Condition: Study involves adult patients (≥18 years) with clinically diagnosed plaque psoriasis as primary condition of interest.
• Population - Condition Specificity: Study includes patients with plaque psoriasis (not focusing exclusively on psoriatic arthritis, pustular psoriasis, or erythrodermic psoriasis).
• Intervention - IL-17A Inhibitors: Study investigates IL-17A inhibitors (e.g., secukinumab, ixekizumab, bimekizumab).
• Intervention - Specificity: Focus on IL-17A inhibitors only (not IL-17 receptor inhibitors or dual inhibitors).
• Outcomes - Inflammatory Measures: Study measures inflammatory biomarkers (cytokines, gene expression) beyond clinical efficacy measures.
• Study Design - Quality: Study must be a randomized controlled trial, cohort study, systematic review, or meta-analysis.
• Treatment Duration: Treatment for at least 4 weeks.
• Confounding Factors - Patient Population: Involves non-immunocompromised patients without active infections.
• Confounding Factors - Concurrent Treatments: Investigates IL-17A inhibitors as monotherapy or without concurrent biologic treatments.

Results indicate that we considered all screening questions together for each paper.

Data extraction

We extracted data across the following columns:

IL-17A Treatment

• IL-17A Inhibitor Used: secukinumab, ixekizumab, AIN457
• Dosage and Administration Route: Various doses and methods (SC, IV, etc.)
• Treatment Duration: Ranges from 6 weeks to 52 weeks.

Inflammatory Pathway Assessment

• Markers Assessed: IL-23, IL-17A, beta-defensin2, IL-36, etc.
• Sample Types Used: Skin biopsies, serum, lesional tissue.

Pathway Effects

• Magnitude of Changes: Notable reductions in inflammatory markers observed, with statistical significance in various studies.

Mechanistic Insights

• Cell Types Affected: Primarily neutrophils, keratinocytes, T cells, and dendritic cells.

Study Design

• Types of Studies: The majority were randomized controlled trials (7/10), with focus on blinding status and control groups.

Patient Population

• Assessment of Severity: Predominantly moderate-to-severe psoriasis using PASI scores with sample sizes varying per study.

Results

Characteristics of Included Studies

This systematic review featured 10 studies that employed three IL-17A inhibitors: secukinumab (6 studies), ixekizumab (2 studies), and AIN457 (1 study). Below are certain findings:

• Study type varied; most were RCTs with significant patient engagement questioning.

Assessment Methods for Inflammatory Pathways

• Studies utilized varying methodologies such as transcriptomics, immunohistochemistry, and RNA sequencing for pathway assessment.

Timeline of Pathway Changes

• Effects were seen within 1-2 weeks across studies. For instance, suppression of IL-23/IL-17 axis was noted as early as week 1.

Mechanistic Insights into IL-17A Pathway Effects

• Cell-Type Specific Effects
  • Evidence indicates neutrophils as early targets of inhibition.
  • Keratinocytes demonstrated significant responsiveness with rapid normalization trends.

Synthesis

The reviewed studies indicated that IL-17A inhibition rapidly affects inflammatory pathways, with notable distinctions between it and IL-23 inhibition concerning speed and cellular targets. The findings emphasize the importance of IL-17A in the treatment paradigm of plaque psoriasis.